Advertisement
Screener

Adicet Bio, Inc. (ACET) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Adicet Bio, Inc. Financing Cash Flow

Adicet Bio, Inc. (ACET) reported Financing Cash Flow of -$7.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05

  • Adicet Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $58.00K, a 78.28% decline year-over-year.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$65.00K.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $75.23M, a 54813.87% increase year-over-year.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$150.00K.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $75.25M, a 32.40% decline from fiscal 2024.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $111.31M, a 47063.98% increase from fiscal 2023.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $236.00K, a 99.43% decline from fiscal 2022.
  • Adicet Bio, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $41.51M, a 82.90% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30$58.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$7.00K
10-Q · filed 2026-08-05
$75.22M
derived: sum of 3 quarters · filed 2026-08-05
$75.08M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$65.00K
10-Q · filed 2026-05-13
$75.17M
derived: sum of 2 quarters · filed 2026-05-13
$75.02M
derived: sum of 3 quarters · filed 2026-05-13
$75.28M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$75.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$75.08M
derived: sum of 2 quarters · filed 2026-03-12
$75.35M
derived: sum of 3 quarters · filed 2026-08-05
$75.25M
10-K · filed 2026-03-12
2025-09-30-$150.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$117.00K
derived: sum of 2 quarters · filed 2026-08-05
$13.00K
10-Q · filed 2025-11-05
$150.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$267.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$163.00K
10-Q · filed 2026-08-05
$300.00K
derived: sum of 3 quarters · filed 2026-08-05
$300.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$104.00K
10-Q · filed 2026-05-13
$33.00K
derived: sum of 2 quarters · filed 2026-05-13
$33.00K
derived: sum of 3 quarters · filed 2026-05-13
$237.00K
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$137.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$137.00K
derived: sum of 2 quarters · filed 2026-03-12
$341.00K
derived: sum of 3 quarters · filed 2026-03-12
$111.31M
10-K · filed 2026-03-12
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$204.00K
derived: sum of 2 quarters · filed 2025-11-05
$111.17M
10-Q · filed 2025-11-05
$111.25M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$204.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$111.17M
10-Q · filed 2025-08-07
$111.25M
derived: sum of 3 quarters · filed 2025-08-07
$111.19M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$110.97M
10-Q · filed 2025-05-06
$111.04M
derived: sum of 2 quarters · filed 2025-05-06
$110.98M
derived: sum of 3 quarters · filed 2025-05-06
$111.21M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$76.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$17.00K
derived: sum of 2 quarters · filed 2025-03-06
$243.00K
derived: sum of 3 quarters · filed 2025-03-06
$236.00K
10-K · filed 2025-03-06
2023-09-30-$59.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$167.00K
derived: sum of 2 quarters · filed 2024-11-06
$160.00K
10-Q · filed 2024-11-06
$464.00K
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$226.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$219.00K
10-Q · filed 2024-08-13
$523.00K
derived: sum of 3 quarters · filed 2024-08-13
$42.70M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$7.00K
10-Q · filed 2024-05-14
$297.00K
derived: sum of 2 quarters · filed 2024-05-14
$42.47M
derived: sum of 3 quarters · filed 2024-05-14
$42.64M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$304.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$42.48M
derived: sum of 2 quarters · filed 2024-03-19
$42.64M
derived: sum of 3 quarters · filed 2024-03-19
$41.51M
10-K · filed 2024-03-19
2022-09-30$42.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$42.34M
derived: sum of 2 quarters · filed 2023-11-08
$41.20M
10-Q · filed 2023-11-08
$138.67M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$163.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$971.00K
10-Q · filed 2023-08-09
$96.49M
derived: sum of 3 quarters · filed 2023-08-09
$96.85M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$1.13M
10-Q · filed 2023-05-09
$96.33M
derived: sum of 2 quarters · filed 2023-05-09
$96.69M
derived: sum of 3 quarters · filed 2023-05-09
$96.66M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$97.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
$97.83M
derived: sum of 2 quarters · filed 2023-03-15
$97.80M
derived: sum of 3 quarters · filed 2023-03-15
$242.69M
10-K · filed 2023-03-15
2021-09-30$362.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$335.00K
derived: sum of 2 quarters · filed 2022-11-08
$145.22M
10-Q · filed 2022-11-08
$145.49M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$27.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$144.86M
10-Q · filed 2022-08-10
$145.13M
derived: sum of 3 quarters · filed 2022-08-10
$145.27M
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31$144.89M
10-Q · filed 2022-05-12
$145.15M
derived: sum of 2 quarters · filed 2022-05-12
$145.30M
derived: sum of 3 quarters · filed 2022-05-12
$145.15M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$267.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$411.00K
derived: sum of 2 quarters · filed 2022-03-15
$261.00K
derived: sum of 3 quarters · filed 2022-03-15
$303.00K
10-K · filed 2022-03-15
2020-09-30$144.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$6.00K
derived: sum of 2 quarters · filed 2021-11-10
$36.00K
10-Q · filed 2021-11-10
-$87.00K
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$150.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$108.00K
10-Q · filed 2021-08-12
-$2.00K
10-Q · filed 2020-07-30
-$231.00K
derived: sum of 3 quarters · filed 2021-08-12
$26.47M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$42.00K
10-Q · filed 2021-05-17
-$1.00K
10-Q · filed 2020-05-07
-$81.00K
derived: sum of 2 quarters · filed 2021-05-17
$26.62M
derived: sum of 3 quarters · filed 2021-05-17
$30.17M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31-$123.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
$26.58M
derived: sum of 2 quarters · filed 2021-03-12
$30.13M
derived: sum of 3 quarters · filed 2021-03-12
$76.94M
10-K · filed 2021-03-12
$56.45M
10-K · filed 2020-03-12
2019-09-30$26.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$30.25M
derived: sum of 2 quarters · filed 2020-11-05
$77.07M
10-Q · filed 2020-11-05
$56.46M
10-Q · filed 2019-11-05
-$1.82M
derived: sum of 4 quarters · filed 2021-03-12
2019-06-30$3.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$50.37M
10-Q · filed 2020-07-30
-$28.53M
derived: sum of 3 quarters · filed 2021-03-12
-$28.53M
derived: sum of 4 quarters · filed 2021-03-12
2019-03-31$46.82M
10-Q · filed 2020-05-07
-$32.08M
derived: sum of 2 quarters · filed 2021-03-12
-$32.08M
derived: sum of 3 quarters · filed 2021-03-12
-$32.08M
derived: sum of 4 quarters · filed 2021-03-12
2018-12-31-$78.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$78.89M
derived: sum of 2 quarters · filed 2021-03-12
-$78.89M
derived: sum of 3 quarters · filed 2021-03-12
$11.05M
10-K · filed 2021-03-12
$89.94M
10-K · filed 2019-03-18
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$0.00
derived: sum of 2 quarters · filed 2019-11-05
$89.94M
10-Q · filed 2019-11-05
$144.32M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
$89.94M
10-Q · filed 2019-08-14
$144.32M
derived: sum of 3 quarters · filed 2020-03-12
$148.82M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$89.94M
10-Q · filed 2019-05-15
$144.32M
derived: sum of 2 quarters · filed 2020-03-12
$148.82M
derived: sum of 3 quarters · filed 2020-03-12
2017-12-31$54.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$58.88M
derived: sum of 2 quarters · filed 2020-03-12
$64.38M
10-K · filed 2020-03-12
2017-09-30$4.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
$10.00M
10-Q · filed 2018-11-13
2017-06-30$5.50M
10-Q · filed 2018-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Valion Bio, Inc. (VBIO)United States$0.077B
Lifevantage Corp (LFVN)United States$0.078B15.40
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41